| Flat View | Friday, May 01, 2026 |
|
| September 2010 | October 2010 | November 2010 |
| Friday, October 01, 2010 |
 |
Secrets Of Batch Process Scale-Up In Radisson Blu, Nice, France ( 9:00 am )
Ensuring Effective Translation of Laboratory Processes to Pilot Plant Scale
Course Aims & Objectives
To teach the practical aspects of designing a scaleable fine-chemical batch process and successfully implementing it at the kilo-lab and pilot plant scale, through an examination of the effects of large-scale operating methods and equipment limitations on process safety, operability, yield, selectivity and product quality.
About this course
Operating a commercially viable chemical process requires a good chemical synthesis to start with, but is also subject to the interplay of a myriad of important physical phenomena – heat transfer, mass transfer, fluid flow, etc. which are traditionally the realm of the chemical engineer. An understanding of these scale-up phenomena is crucial for the laboratory development of processes that will scale successfully.
This course presents an overview of these issues and examines their impact on process operation in the pilot plant and beyond, including scale-up considerations for route selection, raw material charging, reaction steps, workup, crystallization, product isolation, drying, etc. Common bench techniques for each of these steps are contrasted to the safety and operability criteria for successful pilot plant operation. Numerous examples and case histories are presented, along with tips and techniques for operators and experimenters. Heavy emphasis is placed on process safety.
An underlying goal of the course is improving communication and mutual understanding between development team members of different backgrounds; thus, the course is appropriate for synthetic chemists, process development chemists and process engineers with limited pilot plant experience who wish to learn more about the potential pitfalls of scale-up in process development. The course complements the more chemistry-focused Scientific Update course “Chemical Development and Scale-Up in the Fine Chemical and Pharmaceutical Industries”.
Upon completion of the course, participants will be better equipped to:
- Assess process safety and scaleability
- Identify process operations that may be problematic on scale-up
- Design processes that will minimize or avoid scale-up issues
- Select operating methods and equipment for effective scale-up
- Calculate heat removal rates and safe rates of addition of reagents
- Determine mixing requirements for scale-up
- Design crystallizations which can be successfully operated at scale
- Predict the filterability of solid products upon scale-up
- Minimize the effects of scale-up on yield, selectivity and product purity
Url: http://www.scientificupdate.co.uk/training/scheduled-courses/
| |
| Thursday, October 07, 2010 |
|
7th Anti-Infectives Partnering & Deal-Making Summit ( All Day )
Dear Colleague,
Rarely have we faced so many daunting clinical challenges in infectious disease with so few clinical choices in our armamentarium. Equally rarely have we had so few potential agents in development to treat these emerging and expanding pathogens. The increased incidence of multi-resistant Gram positive species such as MRSA in the community and pan-resistant Gram negative organisms in the hospital setting are posing major health care challenges. Efforts to control these and other epidemic species such as Clostridium difficile cannot be achieved with antibiotic stewardship alone, and new agents are needed now.
GTCbio’s 2010 7th Annual Anti-infectives Partnering and Deal-Making Summit taking places on October 7-8, 2010 in Boston will contribute to the on-going battle against the ever-changing infectious threats by having experts with direct experiences in the field discuss a wide variety of topics on infectious diseases. These topics will include reviews of both established and emerging classes of anti-infectives (including antibacterials , antifungals and anti-virals), a US perspective on the regulatory challenges in addition to subjects including portfolio value management, license revenue and patent extension strategies and much more. The agenda also allows time for networking and opportunities to interface with speakers and fellow delegates in a collegial setting. Previous GTCBio conferences have been catalytic to several successful partnerships and in 2010 we expect this trend to continue.
GTCbio’s Anti-Infectives Partnering & Deal Making-Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, explore potential collaborations, and learn about relevant anti-infective issues and deals that will affect the industry. This event also provides a unique venue for attendees to learn about the anti-infective business development trends, the infectious disease markets, and novel technologies that shape up the industry.
The Sessions of the conference include:
I – Recent Advances in Anti-Infectives Development – Part I – Anti-viral
II – Recent Advances in Anti-Infectives Development – Part II – Anti-bacterial
III – Scientific & Regulatory Updates
IV – Innovative Alliance & Licensing Strategies
V – Current Models of R&D Collaboration – Part 1 – Anti-Bacterial
VI – Current Models of R&D Collaboration – Part 2 – Anti-Viral and Anti-Fungal
VI – Investment Opportunities in the Anti-Infectives Space
Register by September 7 for a 10% Discount. Or, Register 2, the 3rd goes free!
Best regards,
2010 Anti-Infectives Summit Advisory Committee
Url: http://www.anti-infectives-conference.com/
| |
| Wednesday, October 20, 2010 |
|
2nd Cancer Targets & Therapeutics ( All Day )
Dear Colleague,
With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets & therapeutics provides new opportunities for the prevention and treatment of several major disease systems. The 2010 2nd Cancer Targets & Therapeutics Conference on October 20-22, 2010 in San Francisco, CA examines new and emerging targets and therapeutics in the area of cancer research. Speakers at the event provide case studies of emerging targets in order to address some of the issues surrounding target-based drug discovery and development.
Registration to this conference will also give you an option of upgrading to unlimited access to the other 3 tracks that are a part of the 6th Modern Drug Discovery & Development Summit and plenary presentations outlined below:
Plenary Session + 4 Tracks
Over 125 leading industrial and academic experts will present at this three-day summit. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. It will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need.
This conference is designed for
- Research & Development Professionals
- Project Managers, Group Leaders and Directors
- Presidents, Vice Presidents, and CEOs
- Manufacturers and Marketers
- Global Project Managers and Strategic Planners
- Business Development and Licensing Executives
- Venture Capitalists and Entrepreneurs
- Academic Researchers and Medical Directors
- Government Representatives
Dedicated networking events have been incorporated to enhance the exchange of information between technology developers and end-users. M3D will provide a great opportunity for companies to expose products and services. Click here to Register for the 6th Modern Drug Discovery & Development Summit or click here to Register for the 2nd Cancer Targets & Therapeutics Conference. Sponsorship and exhibiting opportunities are available in a range of levels, which can be tailored to fit your needs. Please contact 626-256-6405 begin_of_the_skype_highlighting 626-256-6405 end_of_the_skype_highlighting x 102 or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
for more information.
See you in San Francisco,
2010 M3D Organizing Committee
Url: http://gtcbio.com/conferenceDetails.aspx?id=161
| |
|
4th Advances In Stem Cell Discovery & Development ( 8:00 am )
Dear Colleague,
With the lift of the federal ban on stem cell research, new and exciting research opportunities and funding sources will arise. GTCbio`s 2010 4th Advances in Stem Cell Discovery & Development Conference on October 20-22, 2010 in San Francisco, CA presents its attendants with information regarding cutting-edge developments in all areas of stem cell research including the biology, medicine, applications, regulations, and business of stem cells. Recent developments in pre-clinical and clinical trials of stem cell therapy, regenerative medicine and tissue engineering, cancer stem cells, stem cell reprogramming, FDA and NIH policies regarding funding for stem cell research, and private funding from the pharmaceutical industry will be addressed.
Registration to this conference will also give you an option of upgrading to unlimited access to the other 3 tracks that are a part of the 6th Modern Drug Discovery & Development Summit and plenary presentations outlined below:
Plenary Session + 4 Tracks
Over 125 leading industrial and academic experts will present at this three-day summit. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. It will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need.
This conference is designed for
- Research & Development Professionals
- Project Managers, Group Leaders and Directors
- Presidents, Vice Presidents, and CEOs
- Manufacturers and Marketers
- Global Project Managers and Strategic Planners
- Business Development and Licensing Executives
- Venture Capitalists and Entrepreneurs
- Academic Researchers and Medical Directors
- Government Representatives
Dedicated networking events have been incorporated to enhance the exchange of information between technology developers and end-users. M3D will provide a great opportunity for companies to expose products and services. Click here to Register for the 6th Modern Drug Discovery & Development Summit or click here to Register for the 4th Advances in Stem Cell Discovery & Development Conference. Sponsorship and exhibiting opportunities are available in a range of levels, which can be tailored to fit your needs. Please contact 626-256-6405 begin_of_the_skype_highlighting 626-256-6405 end_of_the_skype_highlighting x 102 or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
for more information.
See you in San Francisco,
2010 M3D Organizing Committee
Url: http://gtcbio.com/conferenceDetails.aspx?id=159
| |
|
4th Annual Biomarker Discovery & Development ( All Day )
Dear Colleague,
Rapid advancements in technologies and innovative applications towards translational medicine have thrust biomarkers into the forefront of drug discovery and development in recent years. With many leading Pharmaceutical organizations – including Novartis, Hoffmann-La Roche, Pfizer, Bayer, and Bristol Myers Squibb – having fully integrated biomarker strategies in their development processes, it is clear that biomarkers represent the future of medicine. It is projected that throughout the industry, the biomarker market will reach over $12.8 billion dollars by the year 2012. In order to stay abreast of the changing times and truly understand their full potential, we must explore their versatility as well as their limitations.
GTCbio’s 2010 4th Annual Biomarker Discovery and Development Conference (San Francisco, CA Oct. 20-22, 2010) will present you with comprehensive perspectives on the past and present status of biomarker research. By analyzing where we’ve been, we will be able to project into future trends and understand biomarkers’ central role in the paradigm shift in drug discovery & development toward personalized medicine. Starting with an expose of novel technologies to discover biomarkers, we will then focus on how they are utilized to streamline the development process by reducing time and costs and minimize drug attrition associated with safety concerns. Finally, we will highlight their utility in clinical trials and as companion diagnostics in the clinics. Before you and your organization jump into the fray, make sure that you proceed with a strong foundation! GTCbio’s Biomarker Conference Series have consistently delivered the full picture as well as quality environment to share and gain powerful knowledge and insight into cutting edge research. Come join your colleagues in this timely conference and Rediscover Biomarkers!
Registration to this conference will also give you an option of upgrading to unlimited access to the other 3 tracks that are a part of the 6th Modern Drug Discovery & Development Summit and plenary presentations outlined below:
Plenary Session + 4 Tracks
Over 125 leading industrial and academic experts will present at this three-day summit. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. It will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need.
This conference is designed for
- Research & Development Professionals
- Project Managers, Group Leaders and Directors
- Presidents, Vice Presidents, and CEOs
- Manufacturers and Marketers
- Global Project Managers and Strategic Planners
- Business Development and Licensing Executives
- Venture Capitalists and Entrepreneurs
- Academic Researchers and Medical Directors
- Government Representatives
Dedicated networking events have been incorporated to enhance the exchange of information between technology developers and end-users. M3D will provide a great opportunity for companies to expose products and services. Click here to Register for the 6th Modern Drug Discovery & Development Summit or click here to Register for the 4th Biomarker Discovery and Development Conference. Sponsorship and exhibiting opportunities are available in a range of levels, which can be tailored to fit your needs. Please contact 626-256-6405 begin_of_the_skype_highlighting 626-256-6405 end_of_the_skype_highlighting x 102 or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
for more information.
See you in San Francisco,
2010 M3D Organizing Committee
Url: http://gtcbio.com/conferenceDetails.aspx?id=154
| |
|
5th Biological Therapeutics Research & Development ( All Day )
Dear Colleague,
Research in biologics has become a hot area for many large pharmaceutical companies as expiring patents, a flood of generic drugs and slowing growth in small-molecule drug pipelines have led to decreasing revenues. GTCbio`s 2010 5th Biological Therapeutics Conference on October 20-22, 2010 in San Francisco, CA provides its participants with a current look at biologics and projects into its future with discussions regarding developments and challenges in immunogenicity, humanization, drug delivery techniques for biologics, modern vaccine development, antibodies, and novel protein and peptide delivery. Overcoming the issue of the role of biologics in drug discovery and how to improve upon the length of time a drug remains effective in the body, without losing money, will be addressed.
Registration to this conference will also give you an option of upgrading to unlimited access to the other 3 tracks that are a part of the 6th Modern Drug Discovery & Development Summit and plenary presentations outlined below:
Plenary Session + 4 Tracks
Over 125 leading industrial and academic experts will present at this three-day summit. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. It will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need.
This conference is designed for
- Research & Development Professionals
- Project Managers, Group Leaders and Directors
- Presidents, Vice Presidents, and CEOs
- Manufacturers and Marketers
- Global Project Managers and Strategic Planners
- Business Development and Licensing Executives
- Venture Capitalists and Entrepreneurs
- Academic Researchers and Medical Directors
- Government Representatives
Dedicated networking events have been incorporated to enhance the exchange of information between technology developers and end-users. M3D will provide a great opportunity for companies to expose products and services. Click here to Register for the 6th Modern Drug Discovery & Development Summit or click here to Register for the 5th Biological Therapeutics Research & Development Conference. Sponsorship and exhibiting opportunities are available in a range of levels, which can be tailored to fit your needs. Please contact 626-256-6405 begin_of_the_skype_highlighting 626-256-6405 end_of_the_skype_highlighting x 102 or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
for more information.
See you in San Francisco,
2010 M3D Organizing Committee
Url: http://gtcbio.com/conferenceDetails.aspx?id=160
| |
|
6th Modern Drug Discovery And Development Summit (M3D) ( All Day )
Dear Colleague,
Productivity in the pharmaceutical industry is flagging. It is now clear that the traditional pharmaceutical Research & Development model is not sustainable. New technological innovations in Research & Development may mitigate the situation, but they will not sufficiently reverse the inexorable decline in productivity to salvage the traditional Research & Development model. Instead, radically different business models of Research & Development must be developed, tested and implemented; failure to do so poses a grave threat to the future of the pharmaceutical industry.
Despite such a challenge, new government regulation in areas such as stem cell research and recent advances in technology, as seen in transitional medicine, do present the industry with opportunities to push forward and prosper. Exploring these future opportunities is at the center of the 2010 6th Modern Drug Discovery & Development Summit in San Francisco, CA, on October 20-22, 2010.
Registration to the conference will allow you unlimited access to the 4 tracks and plenary presentations outlined below:
Plenary Session + 4 Tracks
Over 125 leading industrial and academic experts will present at this three-day summit. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. It will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need.
This conference is designed for
- Research & Development Professionals
- Project Managers, Group Leaders and Directors
- Presidents, Vice Presidents, and CEOs
- Manufacturers and Marketers
- Global Project Managers and Strategic Planners
- Business Development and Licensing Executives
- Venture Capitalists and Entrepreneurs
- Academic Researchers and Medical Directors
- Government Representatives
Dedicated networking events have been incorporated to enhance the exchange of information between technology developers and end-users. M3D will provide a great opportunity for companies to expose products and services. Click here to Register for the 6th Modern Drug Discovery & Development Summit. Sponsorship and exhibiting opportunities are available in a range of levels, which can be tailored to fit your needs. Please contact 626-256-6405 begin_of_the_skype_highlighting 626-256-6405 end_of_the_skype_highlighting x 102 or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
for more information.
See you in San Francisco,
2010 M3D Organizing Committee
Url: http://gtcbio.com/conferenceDetails.aspx?id=158
| |
| Thursday, October 21, 2010 |
|
RNAi Asia ( All Day )
Welcome to the 2nd annual RNAi Asia conference and exhibition.
This year's event will be chaired by Dr. Bing Lim, Senior Group Leader, Stem Cell and Developmental Biology, at the Genome Institute of Singapore (GIS). The conference is co-organised with the GIS, a biomedical research institute of the Agency for Science, Technology and Research (A*STAR) in Singapore.
The conference will be co-located with Screening Asia and registered delegates will have access to both meetings.
Make the most of your trip by also attending the co-located market tutorials.
|
Conference Chairman
|
|
 Bing Lim
Senior Group Leader
Genome Institute of Singapore
|
|
Keynote Speakers
|
|
 John Mattick
Professor
University of Queensland
|
|
 Alan Sachs
Vice President, RNA Therapeutics
Merck Research Laboratories
|
Call for Posters
Deadline: 14 October 2010
You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!
Agenda Topics
- Target Discovery and Validation
- Transfection
- siRNA Therapeutics
- in vivo RNAi
- siRNA library screens
- microRNAs in
- Disease Biology
- Stem Cell Biology
- Diagnostics
- Virology
- Biogenesis
- Development
Url: http://www.selectbiosciences.com/conferences/RNAiA2010/
| |
|
Screening Asia ( All Day )
Welcome to the inaugural Screening Asia conference and exhibition.
This year's event will be held in Singapore.
The conference will be co-located with RNAi Asia. Registered delegates will have access to both meetings ensuring a very cost-effective trip.
Make the most of your trip by also attending the co-located training courses or market tutorials.
|
Keynote Speaker
|
|
 Rathnam Chaguturu
Director
High Throughput Screening Laboratories University of Kansas
|
|
 Paul Orange
Business Leader,
Bio-Discovery,
Perkin Elmer
|
Call for Posters
Deadline: 14 October 2010
You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!
Agenda Topics
- High Content Screening
- Assay Development and Analysis
- Novel Screening Platforms and Technologies
- Screening and Drug Discovery
- Biosimilars & Biologics
- Natural Products Screening
Sponsorship and Exhibition Opportunities
Aaron Woodley, Exhibition Manager
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+44 (0)1787 315129 begin_of_the_skype_highlighting +44 (0)1787 315129
Url: http://www.selectbiosciences.com/conferences/SA2010/
| |
| Thursday, October 28, 2010 |
|
Microarray World Congress ( All Day )
Welcome to the 2nd annual Microarray World Congress where you will hear about the latest developments and applications in the rapidly expanding field of microarrays. This year's event will be held in San Diego.
The conference will be co-located with the Lab-on-a-Chip World Congress, Molecular Diagnostics World Congress and Single Cell Analysis Summit. Registered delegates will have access to all four meetings ensuring a very cost-effective trip.
Register now and save up to $100!
|
Keynote Speakers
|
|
 Thomas Joos
Head, Biochemistry/NMI Natural and Medical Sciences Institute at the University of Tuebingen
|
|
 Marc Madou
Professor, University of California, Irvine
|
Free Workshop
Call for Posters
Deadline: 10 September 2010
You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!
Agenda Topics
- CGH Arrays
- ChIP-on-ChIP
- Bioinformatics for microarrays
- Methylation Detection
- Protein and Antibody Arrays
- Lipid Arrays
- Tissue Arrays
- Emerging Technologies
Sponsorship and Exhibition Opportunities
Aaron Woodley, Exhibition Manager
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+44 (0)1787 315129 begin_of_the_skype_highlighting +44 (0)1787 315129
Url: http://www.selectbiosciences.com/conferences/MWC2010
| |
|
|
| Saturday, October 30, 2010 |
|
Secrets Of Batch Process Scale-Up In Radisson Blu, Nice, France ( 9:00 am )
Ensuring Effective Translation of Laboratory Processes to Pilot Plant Scale
Course Aims & Objectives
To teach the practical aspects of designing a scaleable fine-chemical batch process and successfully implementing it at the kilo-lab and pilot plant scale, through an examination of the effects of large-scale operating methods and equipment limitations on process safety, operability, yield, selectivity and product quality.
About this course
Operating a commercially viable chemical process requires a good chemical synthesis to start with, but is also subject to the interplay of a myriad of important physical phenomena – heat transfer, mass transfer, fluid flow, etc. which are traditionally the realm of the chemical engineer. An understanding of these scale-up phenomena is crucial for the laboratory development of processes that will scale successfully.
This course presents an overview of these issues and examines their impact on process operation in the pilot plant and beyond, including scale-up considerations for route selection, raw material charging, reaction steps, workup, crystallization, product isolation, drying, etc. Common bench techniques for each of these steps are contrasted to the safety and operability criteria for successful pilot plant operation. Numerous examples and case histories are presented, along with tips and techniques for operators and experimenters. Heavy emphasis is placed on process safety.
An underlying goal of the course is improving communication and mutual understanding between development team members of different backgrounds; thus, the course is appropriate for synthetic chemists, process development chemists and process engineers with limited pilot plant experience who wish to learn more about the potential pitfalls of scale-up in process development. The course complements the more chemistry-focused Scientific Update course “Chemical Development and Scale-Up in the Fine Chemical and Pharmaceutical Industries”.
Upon completion of the course, participants will be better equipped to:
- Assess process safety and scaleability
- Identify process operations that may be problematic on scale-up
- Design processes that will minimize or avoid scale-up issues
- Select operating methods and equipment for effective scale-up
- Calculate heat removal rates and safe rates of addition of reagents
- Determine mixing requirements for scale-up
- Design crystallizations which can be successfully operated at scale
- Predict the filterability of solid products upon scale-up
- Minimize the effects of scale-up on yield, selectivity and product purity
Url: http://www.scientificupdate.co.uk/training/scheduled-courses/
| |
|
|
Jon Cooper
